OBJECTIVES: This study clarified the results of surgery for primary lung cancer based on the new international staging system. BACKGROUND: On December 1997, the Japan Lung Cancer Society adopted a new TNM staging system which had already received international recognition. SUBJECTS AND METHODS: The subjects of this study were 1062 consecutive previously untreated patients who underwent pulmonary resection for primary non-small cell lung cancer between January 1975 and December 1992. RESULTS: The postoperative 5-year survival rate for all patients was 58.5%. Pathological staging demonstrated a survival rate which was 73.2% in stage I, 46.8% in stage II, 26.7% in stage III, and 20.0% in stage IV. In the staging subgroups, the survival rate was 79.6% in stage IA, 62.4% in stage IB, 62.2% in stage IIA, 42.0% in stage IIB, 26.9% in stage IIIA, and 26.3% in stage IIIB. Concerning the pm patients, the survival rate was 20.2% in pm1 and 20.0% in pm2, while the survival rate of the patients with N0 was 45.7% in pm1 and 40.0% in pm2. CONCLUSIONS: A significant difference in the 5-year survival rate was recognized between the new stages IA and IB, and between the new stages IIA and IIB. When pm patients are diagnosed without lymph node metastasis, the opportunity for resection should not be lost.
OBJECTIVES: This study clarified the results of surgery for primary lung cancer based on the new international staging system. BACKGROUND: On December 1997, the Japan Lung Cancer Society adopted a new TNM staging system which had already received international recognition. SUBJECTS AND METHODS: The subjects of this study were 1062 consecutive previously untreated patients who underwent pulmonary resection for primary non-small cell lung cancer between January 1975 and December 1992. RESULTS: The postoperative 5-year survival rate for all patients was 58.5%. Pathological staging demonstrated a survival rate which was 73.2% in stage I, 46.8% in stage II, 26.7% in stage III, and 20.0% in stage IV. In the staging subgroups, the survival rate was 79.6% in stage IA, 62.4% in stage IB, 62.2% in stage IIA, 42.0% in stage IIB, 26.9% in stage IIIA, and 26.3% in stage IIIB. Concerning the pm patients, the survival rate was 20.2% in pm1 and 20.0% in pm2, while the survival rate of the patients with N0 was 45.7% in pm1 and 40.0% in pm2. CONCLUSIONS: A significant difference in the 5-year survival rate was recognized between the new stages IA and IB, and between the new stages IIA and IIB. When pm patients are diagnosed without lymph node metastasis, the opportunity for resection should not be lost.
Authors: R Ginsberg; J Cox; M Green; H Bulzebruck; D Grunenwald; P Harper; J Jett; T LeChevalier; F Mornex; C Scott; R Tsuchiya Journal: Lung Cancer Date: 1997-06 Impact factor: 5.705
Authors: K Usuda; Y Saito; M Sato; T Sakuma; H Aikawa; H Takahashi; G Okaniwa; M Handa; S Takahashi; S Fujimura Journal: Nihon Kyobu Geka Gakkai Zasshi Date: 1996-05